Recursion trumpeted the results as if they were successful, but this program isn't going anywhere fast. The company still hasn't announced plans to launch a phase 3 study for REC-994, the ...

In theory, Recursion's AI models tell it which new drug candidates are most likely to succeed once tested with animals and then humans. In practice, though, ...

Machine-learning techniques keep improving efficiency in one industry after another. One corner of the economy where investors expect another big leap forward is the world of drug development. For ...